Overview

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.

Phase:

Phase 2

Details

Lead Sponsor:

Heinrich-Heine University, Duesseldorf

Treatments:

Azacitidine